STOCK TITAN

AnaptysBio (ANAB) Financials

ANAB NASDAQ
FY2025 annual
Revenue $234.6M +157.0% YoY
Net Income -$13.2M n/m YoY
EPS (Diluted) -$0.44 n/m YoY
Free Cash Flow $19.6M n/m YoY
Market Cap $1.4B as of Nov 20, 2026
Price / Sales 5.9x on $234.6M revenue, FY2025
Price / Earnings n/m net loss, so no earnings multiple, FY2025
Price / Book 66.6x on $20.8M equity, Q1 FY2027

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2027, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2027, filed Nov 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ANAB SEC filings page.

AnaptysBio, Inc. (ANAB) reported $234.6M in revenue for fiscal year 2025, up 157.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ANAB FY2025

Revenue scale-up transformed reported operating results, but cash conversion and thin equity capitalization remain the defining mechanics of AnaptysBio's FY2025.

In FY2025, operating income reached $226.9M while operating cash flow was only $19.7M, showing that reported operating profit did not translate proportionally into cash earnings. The company still reported a net loss of $13.2M despite free cash flow of $19.6M, so operating profitability and bottom-line results were shaped by items below operating income.

Revenue rose 157.0% while R&D remained 58.0% of sales; the model is still development-intensive despite the scale-up. SG&A fell 16.8%, helping explain the operating-margin expansion to 96.7% without requiring a pricing-power claim.

The balance sheet combines a 9.1x current ratio with liabilities equal to 89.8% of assets and liabilities at 8.8x equity: near-term coverage looks ample, but the equity cushion is thin. The $68.6M share buyback exceeded the year's $19.6M free cash flow, indicating capital allocation was not funded solely by current-period cash generation.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 82 / 100
Financial Health Score 82/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of AnaptysBio, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
87

AnaptysBio, Inc. held $211.6M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $19.7M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and AnaptysBio, Inc. scores 87/100 among other emerging companies.

Dilution
71

Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. AnaptysBio, Inc. scores 71/100 on it among other emerging companies.

R&D Intensity
100

AnaptysBio, Inc. spent $136.0M on research and development in fiscal year 2025, which was 1765.6% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and AnaptysBio, Inc. scores 100/100 among other emerging companies.

Revenue Progress
94

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. AnaptysBio, Inc. scores 94/100 on it among other emerging companies.

Burn Trend
92

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. AnaptysBio, Inc. scores 92/100 on it among other emerging companies.

Balance Sheet
49

AnaptysBio, Inc.'s cash, cash equivalents and investments came to $211.6M at the end of fiscal year 2025, against $327.2M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and AnaptysBio, Inc. scores 49/100 among other emerging companies.

Altman Z-Score Safe
3.30

AnaptysBio, Inc. scores 3.30, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $1.4B against total liabilities of $327.2M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
5/7

AnaptysBio, Inc. passes 5 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) passes.

Earnings Quality Mixed
N/A

AnaptysBio, Inc. reported a net loss of $13.2M while generating $19.7M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$30.3M
YoY+18.5%

AnaptysBio, Inc. generated $30.3M in revenue in Q1 2027. This represents an increase of 18.5% from the same quarter a year earlier.

EBITDA
$19.9M
YoYn/m

AnaptysBio, Inc.'s EBITDA was $19.9M in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Net Income
$3.9M
YoYn/m

AnaptysBio, Inc. reported $3.9M in net income in Q1 2027. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

EPS (Diluted)
$0.11
YoYn/m

AnaptysBio, Inc. earned $0.11 per diluted share (EPS) in Q1 2027. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Cash & Balance Sheet

Cash & Debt
$135.4M
YoY-45.5%
QoQ+1.2%
5Y CAGR-16.6%
10Y CAGR+11.1%

AnaptysBio, Inc. held $135.4M in cash as of Q1 2027; no long-term debt figure is on record for that period.

Shares Outstanding
30M
YoY+2.2%
QoQ-0.6%
5Y CAGR+1.6%

AnaptysBio, Inc. had 30M shares outstanding in Q1 2027. This represents an increase of 2.2% from the same quarter a year earlier. Against the prior quarter it is down 0.6%.

Free Cash Flow

Not reported for Q1 2027.

Dividends Per Share

Not reported for Q1 2027.

Margins & Returns

Operating Margin
65.8%

AnaptysBio, Inc.'s operating margin was 65.8% in Q1 2027, reflecting core business profitability. No change is given against Q1 2026: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin
12.8%

AnaptysBio, Inc.'s net profit margin was 12.8% in Q1 2027, showing the share of revenue converted to profit. No change is given against Q1 2026: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity
18.6%
YoY+433.5pp

AnaptysBio, Inc.'s quarterly ROE was 18.6% in Q1 2027: one quarter's net income over shareholder equity, not annualized. This is up 433.5 percentage points from the same quarter a year earlier.

Gross Margin

Not reported for Q1 2027.

Capital Allocation

Share Buybacks
$0
YoYn/m
QoQn/m

AnaptysBio, Inc. repurchased no shares in Q1 2027. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

R&D Spending

Not reported for Q1 2027.

Capital Expenditures

Not reported for Q1 2027.

ANAB Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ANAB quarterly income statement
MetricQ1'2710-QQ4'2610-KTQ1'2610-QQ4'2510-KTQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KT
Revenue$30.3M+18.5%N/A$25.6M-8.0%$108.2M+151.1%$76.3M+154.3%$22.3M+102.9%$27.8M+286.8%$43.1M+378.8%
R&D ExpensesN/AN/A$34.0M-17.5%$25.6M-40.0%$31.4M-25.6%$37.8M-9.9%$41.2M+11.2%$42.6M+27.0%
SG&A Expenses$11.6M-55.6%N/A$26.2M+85.4%$15.8M+54.9%$1.1M-89.7%$10.6M+14.1%$14.1M+14.5%$10.2M-0.8%
Operating Income$19.9Mn/mN/A-$34.6Mn/m$66.9Mn/m$77.3Mn/m-$26.2Mn/m-$27.5Mn/m-$9.7Mn/m
EBITDA$19.9Mn/mN/A-$34.5Mn/mN/A$77.3Mn/mN/A-$27.4Mn/mN/A
Income Tax-$608K-1620.0%N/A$40K-9.1%$81Kn/m$269Kn/m$39K+333.3%$44Kn/m-$6Kn/m
Net Income$3.9Mn/mN/A-$52.9Mn/m$49.6Mn/m$15.1Mn/m-$38.6Mn/m-$39.3Mn/m-$21.8Mn/m
EPS (Basic)$0.13n/mN/A-$1.84n/m$1.70n/m$0.54n/m-$1.34n/m-$1.28n/m-$0.66n/m
EPS (Diluted)$0.11n/mN/A-$1.84n/m$1.70n/m$0.52n/m-$1.34n/m-$1.28n/m-$0.66n/m
Diluted Shares (Avg)35M+22.2%N/A29M-6.4%N/A29M+0.4%29M+5.3%31M+14.3%N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.

ANAB Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ANAB quarterly balance sheet
MetricQ1'2710-QQ4'2610-QQ1'2610-QQ4'2510-KTQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KT
Total Assets$307.0M-6.9%$317.0M-13.0%$329.7M-21.9%$364.4M-24.7%$353.1M-28.4%$335.3M-21.6%$422.1M+4.0%$483.8M+7.0%
Current Assets$188.4M-40.4%$198.4M-43.3%$316.1M-12.9%$350.3M-18.9%$330.6M-26.3%$291.9M-20.5%$363.1M-2.5%$431.9M+6.2%
Cash & Equivalents$135.4M-45.5%$133.8M-3.2%$248.5M+151.9%$138.2M+498.8%$109.8M-42.7%$44.3M-38.3%$98.6M+83.7%$23.1M-35.8%
Short-Term Investments$17.6M-53.7%$30.3M-58.7%$38.0M-84.3%$73.4M-72.0%$139.1M-41.7%$221.4M-20.6%$241.3M-19.8%$262.3M-26.1%
Long-Term Investments$0n/m$0n/m$0-100.0%$0-100.0%$7.7M-72.4%$28.0M-34.4%$43.0M+178.0%$35.5M+31.2%
Total Liabilities$286.2M-9.7%$306.4M-6.4%$316.9M-18.3%$327.2M-20.8%$382.5M-6.5%$380.0M-9.0%$388.0M+8.4%$413.0M+13.4%
Current Liabilities$22.4M-46.2%$35.4M-8.5%$41.7M-5.3%$38.6M-15.0%$38.1M-13.2%$35.5M-12.1%$44.0M+36.3%$45.4M+21.3%
Non-Current Liabilities$263.8M-4.2%$271.0M-6.1%$275.2M-20.0%$288.6M-21.5%$344.4M-5.7%$344.5M-8.7%$344.0M+5.6%$367.5M+12.5%
Total Equity$20.8M+63.3%$10.6M-71.6%$12.7M-62.5%$37.2M-47.5%-$29.4M-134.9%-$44.7M-552.8%$34.0M-28.8%$70.9M-19.6%
Retained Earnings-$637.7Mn/m-$641.6Mn/m-$825.4Mn/m-$772.6Mn/m-$822.2Mn/m-$837.3Mn/m-$798.7Mn/m-$759.3Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

ANAB Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ANAB quarterly cash flow statement
MetricQ1'2710-QQ4'2610-KTQ1'2610-QQ4'2510-KTQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KT
Operating Cash Flow-$9.5Mn/m-$26.6M-127.2%-$25.9Mn/m$98.0Mn/m-$27.4Mn/m-$40.2Mn/m-$10.7Mn/m-$66.7Mn/m
Depreciation & Amortization$5K-96.2%N/A$130K-11.0%N/A$4K-97.2%N/A$146K-10.4%N/A
Stock-Based Compensation$3.2M-77.4%N/A$14.2M+55.0%N/A$207K-97.5%$9.2M+22.5%$9.2M-9.5%N/A
Capital ExpendituresN/AN/A$17K-51.4%$1K-99.6%$12K-65.7%$39K+18.2%$35K+29.6%$263K-6.1%
Free Cash FlowN/AN/A-$25.9Mn/m$98.0Mn/m-$27.4Mn/m-$40.3Mn/m-$10.7Mn/m-$66.9Mn/m
Investing Cash Flow$12.6M-64.0%$7.6M-89.7%$35.0M+135.6%$73.5Mn/m$47.6M-18.8%$92.1Mn/m$14.8M-78.4%-$93.4M-290.0%
Financing Cash Flow-$1.5M-222.4%-$95.6Mn/m$1.2Mn/m-$43.1M-256.5%-$10.4M-114.6%-$50.5M-220.5%-$28.6Mn/m$27.6Mn/m
Share Buybacks$0n/m$0-100.0%$0-100.0%$3.4M+642.1%$9.7Mn/m$51.1Mn/m$4.4Mn/m$456Kn/m

Not reported in any period shown, so not listed: Dividends Paid.

ANAB Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ANAB quarterly financial ratios
MetricQ1'2710-QQ4'2610-KTQ1'2610-QQ4'2510-KTQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KT
Operating Margin65.8%N/A-135.5%61.8%+84.2pp101.3%-117.5%-99.2%-22.4%
Net Margin12.8%N/A-206.9%45.8%+96.4pp19.8%-173.5%-141.6%-50.5%
Return on Equity18.6%+433.5ppN/A-414.9%-299.3pp133.3%+164.1ppN/AN/A-115.6%-23.6pp-30.7%+17.2pp
Return on Assets1.3%+17.3ppN/A-16.0%-6.7pp13.6%+18.1pp4.3%+10.9pp-11.5%-0.6pp-9.3%+1.5pp-4.5%+4.8pp
Current Ratio8.40+0.8x5.61-3.5x7.58-0.7x9.07-0.4x8.68-1.5x8.22-0.9x8.25-3.3x9.51-1.4x
Liabilities-to-Equity13.75-11.1x28.95+20.2x24.86+13.5x8.79+3.0xN/AN/A11.41+3.9x5.83+1.7x
Asset Turnover0.100.0xN/A0.080.0x0.30+0.2x0.22+0.2x0.070.0x0.070.0x0.09+0.1x
FCF MarginN/AN/A-101.5%90.5%-35.9%-2.1pp-180.9%-38.7%-155.3%

Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
AnaptysBio, Inc. ANAB FY2025 $234.6M -$13.2M -5.6% $1.4B 82/100
Sarepta Therapeutics, Inc. SRPT FY2025 $2.2B -$713.4M -32.5% $1.4B 42/100
Nurix Therapeutics, Inc. NRIX FY2025 $84.0M -$264.5M N/A $1.4B 54/100
uniQure N.V. QURE FY2025 $16.1M -$199.0M N/A $1.4B 58/100
Zenas BioPharma, Inc. ZBIO FY2025 $10.0M -$377.7M N/A $1.6B 36/100
Precigen, Inc. PGEN FY2025 $9.7M -$250.6M N/A $1.5B 51/100

Frequently Asked Questions

AnaptysBio, Inc. (ANAB) reported $234.6M in total revenue for fiscal year 2025. This represents a 157.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

AnaptysBio, Inc. (ANAB) revenue grew by 157.0% year-over-year, from $91.3M to $234.6M in fiscal year 2025.

No, AnaptysBio, Inc. (ANAB) reported a net loss of $13.2M in fiscal year 2025, with a net profit margin of -5.6%.

AnaptysBio, Inc. (ANAB) reported diluted earnings per share of -$0.44 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

AnaptysBio, Inc. (ANAB) had EBITDA of $226.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

AnaptysBio, Inc. (ANAB) had an operating margin of 96.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

AnaptysBio, Inc. (ANAB) had a net profit margin of -5.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

AnaptysBio, Inc. (ANAB) has a return on equity of -35.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

AnaptysBio, Inc. (ANAB) generated $19.6M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

AnaptysBio, Inc. (ANAB) generated $19.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

AnaptysBio, Inc. (ANAB) had $364.4M in total assets as of fiscal year 2025, including both current and long-term assets.

AnaptysBio, Inc. (ANAB) invested $87K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

AnaptysBio, Inc. (ANAB) invested $136.0M in research and development during fiscal year 2025.

Yes, AnaptysBio, Inc. (ANAB) spent $68.6M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

AnaptysBio, Inc. (ANAB) had 29M shares outstanding as of fiscal year 2025.

AnaptysBio, Inc. (ANAB) had a current ratio of 9.07 as of fiscal year 2025, which is generally considered healthy.

AnaptysBio, Inc. (ANAB) had a liabilities-to-equity ratio of 8.79 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

AnaptysBio, Inc. (ANAB) had a return on assets of -3.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

AnaptysBio, Inc. (ANAB) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $1.4B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

AnaptysBio, Inc. (ANAB) trades at 5.9x sales, its market capitalization divided by $234.6M revenue, FY2025. The market capitalization is $1.4B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

AnaptysBio, Inc. (ANAB) has an Altman Z-Score of 3.30, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

AnaptysBio, Inc. (ANAB) has a Piotroski F-Score of 5 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

AnaptysBio, Inc. (ANAB) reported a net loss of $13.2M while generating $19.7M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

AnaptysBio, Inc. (ANAB) scores 82 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top